Strides Arcolab today announced it had reached an agreement to acquire the Milan fermentation assets of Disapa S.p.A, Italy. Financial details of the transaction were not disclosed.According to an official release issued by the company to the BSE today, the acquisition would be carried out through a special purpose vehicle incorporated in Italy, which will be owned by Strides Arcolab International.Commenting on the acquisition, Arun Kumar, VC & MD, Strides Arcolab Group said: "The acquisition will give us immediate access to a USFDA and EU approved facility with strong history of technology and fermentation skills. A significant part of Strides dosage form businesses are based on fermentation active pharmaceutical ingredients (APIs). Diaspa delivers the integration needs for us in this crucial space. We further intend to harness the existing customer base and product capabilities of Diaspa and aim to become a leading player in the fermentation space. We are also delighted with the strong technology and management bandwidth Diaspa brings along with this acquisition".
